A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Umeclidinium (Primary) ; Fluticasone furoate; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Nov 2017 Planned End Date changed from 12 Jun 2018 to 31 May 2018.
- 13 Nov 2017 Planned primary completion date changed from 12 Jun 2018 to 31 May 2018.
- 13 Nov 2017 Status changed from recruiting to active, no longer recruiting.